Due to the upregulation of CCL25 and recruitment of CCR9+ immune cells in the gut of inflammatory bowel disease (IBD) patients, CCR9 is considered as a potential therapeutic target to control gut inflammation (1, 10, 11). The gene discussed is CCL25; the disease is inflammatory bowel disease.